Divi's Laboratories has reported results for fourth quarter (Q4) and year ended March 31, 2024.
The company has reported 66.46% rise in its net profit at Rs 531 crore for the quarter under review as compared to Rs 319 crore for the same quarter in the previous year. Total income of the company increased by 18.44% at Rs 2,338 crore for Q4FY24 as compared Rs 1,974 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 67.60% rise in its net profit at Rs 538 crore for fourth quarter ended March 31, 2024 as compared to Rs 321 crore for the same quarter in the previous year. Total income of the company increased by 18.10% at Rs 2,382 crore for Q4FY24 as compared Rs 2,017 crore for the corresponding quarter previous year.
For the year ended March 31, 2024, the company has reported 12.83% fall in its net profit at Rs 1,576 crore as compared to Rs 1,808 crore for the previous year. However, total income of the company increased by 0.35% at Rs 8,002 crore for year under review as compared to Rs 7,974 crore for year ended March 31, 2023.
For the year ended March 31, 2024, on the consolidated basis, the company has reported 12.28% fall in its net profit at Rs 1,600 crore as compared to Rs 1,824 crore for the previous year. However, total income of the company increased by 0.89% at Rs 8,184 crore for year under review as compared to Rs 8,112 crore for year ended March 31, 2023.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1786.85 |
Dr. Reddys Lab | 1173.55 |
Cipla | 1525.50 |
Lupin | 2018.35 |
Zydus Lifesciences | 859.10 |
View more.. |